Asset profile
LM11A-31
Small molecule
Evidence outlook · lead readout
NCT03069014 · Mild to Moderate Alzheimer's Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT03069014: The study randomized 242 participants to two LM11A-31-BHS doses or placebo and masked participants, care providers, and investigators. Its primary endpoint concerned adverse events and other safety measures, but no results were posted, so whether the primary comparison was favorable or statistically significant cannot be determined.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.